Anavex Life Sciences Corp (AVXL)

[RedShoulder]

PDD data to date, see slide # 23 -27:

How would you describe the progress on PD?

I'm highly optimistic that FDA and TGA/SAS will approve A2-73 Blarcamesine for PDD on this data alone. There are no other drugs on the market that can "improve" PDD like Anavex can on the high dose. The bar is so low it is in the grass. Anavex has the FDA and TGA
approval IMO after the pivotal trial coming up soon.

PDD and PD is a huge revenue market, this disease is the largest population in the CNS market after Alzheimer.

I'm looking for that peer review of the PDD/PD top line results before Missling speaks a word about the details and specifics. However a great clue is slide 26 in the recent Corporate Presentation:

https://www.anavex.com/wp-content/uploads/2021/02/Anavex-Presentation-February-2021.pdf

"Significant Improvements in Episodic Memory with Increased Dose"

1) Those on the Placebo continued to decline in the disease.

2) Those on Low dose did not decline but maintained as when started.

3) Those on High dose improved.